重组人纤溶酶原Kringle1-5的制备及其

为了研究重组人纤溶酶原 Kringle1-5(K1-5)的抗血管生成活性及其对内皮细胞增殖的影响, 通过PCR扩增人纤溶酶原K1-5 cDNA,定向克隆于原核表达载体pET30a(+)中,构建重组表达载体pET-K1-5, 转化E.coli BL21(DE3), IPTG诱导表达,SDS-PAGE 和Western 杂交检测K1-5的表达。鸡胚尿囊膜 (CAM) 实验和MTT实验分别检测重组人纤溶酶原Kringle1-5对鸡胚新生血管生成和内皮细胞的抑制作用。结果表明,IPTG诱导原核表达载体pET-K1-5在E.coli BL21(DE3)中的表达量约占菌体总蛋白量的32%, K1-5主要以包涵体形式存在,包涵体经过洗涤、溶解、Ni-spin 亲合柱层析纯化以及蛋白质复性等步骤后,获得了纯度约为96%的重组K1-5蛋白。CAM实验表明,原核表达的重组人K1-5能有效地按剂量依赖的方式抑制鸡胚新生血管的形成。MTT实验结果显示,重组人K1-5特异地抑制内皮细胞的增殖, 而对非内皮细胞无抑制作用。     

Recombinant mouse canstatin inhibits chicken embryo chorioallantoic membrane angiogenesis and endothelial cell proliferation

It is now well documented that the growth and meta-stasis of malignant tumors beyond a few mm3 dependlargely upon the formation of networks known as angio-genesis [1–3]. Several studies have shown that the tumormass can be restricted to within a certain …     

重组人纤溶酶原Kringle1-3的生物学活性鉴定

目的：检测重组人纤溶酶原Kringle1-3（K1-3）的生物学活性。方法：用含重组人纤溶酶原K1-3基因的表达载体pET21a-Angio（K1-3）转化表达宿主菌大肠杆菌BL21（DE3）后诱导表达,表达产物经溶解、复性和纯化后,进行SDS-PAGE,计算其相对分子质量;用BCA法测蛋白浓度,用细胞抑制实验（MTT法）和鸡胚绒毛膜尿囊膜（CAM）实验鉴定纯化产物对血管内皮细胞增殖和血管生成的抑制效果。结果：表达产物的相对分子质量为38000,与预期值一致;细胞抑制实验和CAM实验结果表明表达产物具有特异抑制血管内皮细胞增殖、血管生成的功能。结论：所纯化的重组人纤溶酶原K1-3具有抑制血管内皮细胞的生物学活性,为该蛋白在病理性血管疾病等方面的应用研究提供了材料。     

人纤溶酶原Kringle 1—5结构域的表达及活性鉴定

利用RT PCR的方法从人肝癌细胞株HepG2细胞内获得了编码人纤溶酶原 (hPlasminogen)的Kringle 1到 5(简称K1- 5 )的cDNA ,将其克隆到表达载体pHIL S1中。将重组载体pHIL K1- 5转化毕赤酵母GS115 ,得到的重组菌株用甲醇进行诱导表达 ,并利用赖氨酸亲和柱纯化重组蛋白质。重组蛋白质K1- 5能特异性地按剂量依赖的方式抑制碱性成纤维细胞生长因子 (bFGF)刺激的牛主动脉内皮细胞 (BAEC)的增殖 ,浓度为 14mg L时达到最大抑制效果的 5 0 % ;K1- 5能抑制bFGF引起的BAEC的迁移 ,5 0mg L的K1- 5对BAEC迁移的抑制率为 4 7% ;K1- 5还能影响BAEC细胞的周期 ,14mg L的K1- 5使细胞在G0 ～G1 期积聚。     

A novel peptide isolated from a phage display library inhibits tumor growth and metastasis by blocking the binding of vascular endothelial growth factor to its kinase domain receptor

Vascular endothelial growth factor (VEGF), one of the most important angiogenic factors, plays an essential role in both physiological and pathological angiogenesis. The VEGF receptor KDR/Flk-1 (a kinase domain receptor) mediates various biological activities of VEGF related to proliferation, differentiation, and migration of endothelial cells. Here we present a novel peptide designated K237-(HTMYYHHYQHHL), which was isolated from a phage-displayed peptide library, binding to KDR with high affinity and specificity. By interfering with the VEGF-KDR interaction, the peptide K237 inhibited proliferation of cultured primary human umbilical vein endothelial cells induced by recombinant human VEGF(165) in a dose-dependent and cell type-specific manner. The peptide also exerted an anti-angiogenesis activity in vivo as revealed using the chick embryo chorioallantoic membrane angiogenesis assay. Moreover, the peptide K237 significantly inhibited the growth of solid tumors implanted beneath the breasts and their metastases to lungs in severe combined immunodeficient mice. Taken together, these findings suggest that the peptide K237 can functionally disrupt the interaction between VEGF and the KDR receptor and cause potent biological effects that include the inhibition of angiogenesis and tumor growth. As a consequence, this peptide (and its future derivatives) may have use as a potential cancer therapy.     

重组小鼠canstatin N端片段对鸡胚新生血管生成的抑制作用(英)

为了研究重组小鼠canstatin N端片段的体内抗血管生成活性, 通过PCR扩增小鼠canstatin N端片段cDNA,定向克隆于原核表达载体pET30a(+)中,构建小鼠canstatin N端片段重组表达载体pET-mCanN, 转化E.coli BL21(DE3), IPTG诱导表达,SDS-聚丙烯酰胺凝胶电泳(SDS-PAGE)和蛋白质印迹检测小鼠canstatin N端片段的表达. 结果表明,IPTG诱导原核表达载体pET-mCanN在大肠杆菌E.coli BL21(DE3)中高效表达, 小鼠canstatin N端片段表达量约占菌体总蛋白量的18%, 小鼠canstatin N端片段主要以包涵体形式存在,包涵体经过洗涤、裂解、Ni-spin column亲合柱层析以及蛋白质复性等步骤纯化后,获得了纯度约为92%的重组小鼠canstatin N端片段. 鸡胚绒毛尿囊膜(chicken embryo choriollantoic membrane,CAM)实验表明,原核表达的小鼠canstatin N端片段能有效地按剂量依赖的方式抑制鸡胚新生血管的形成.     

人血纤维蛋白溶酶原K5环的基因合成、表达、纯化与活性鉴定

 根据大肠杆菌遗传密码的偏爱性 ,人工合成人血纤维蛋白溶酶原 K5全基因 ,并在原核系统中以硫氧还蛋白融合蛋白的形式实现了高效表达 .重组蛋白通过 Ni2 +金属螯合层析得到初步纯化 ,通过肠激酶切割去除了融合标签 .应用鸡胚尿囊膜实验检测切割后的 rh K5的生物学活性 ,发现与对照组相比 ,rh K5能明显地降低血管管径、血管总面积以及血管总面积与视野面积的比值 ,表明切割后的产物具有显著抑制新生血管生成的生物学活性 .为进一步研究和开发抗血管生成药物奠定了基础 .     

Expression and purification of human endostatin from Hansenula polymorpha A16

Endostatin (EDN), an endogenous angiogenesis inhibitor of 20 kDa, was originally isolated from the supernatant of culture murine hemangioendothelioma cell line. Interest in EDN arises from its therapeutic potential as anti-tumor and anti-angiogenesis agents. However, it is difficult to obtain sufficient quantities of native EDN from its natural resources. We report here the construction of a pMIRH-type vector pLRG29 by introducing the 25s rDNA of Hansenua wingei and the Km(R) gene into the YIp vector pSML12 and the EDN expression vector pLRG-EDN by cloning the human EDN cDNA into pLRG29. Human EDN was expressed in Hansenula polymorpha (H.p.) A16 (pLRG-EDN) as a secreted soluble protein. The yield of the secreted EDN was 65 mg/L in shake flask. The secreted EDN was purified to a purity of 98 % by the use of SP Sepharose FF ion-exchange chromatography and Sepharose-heparin Hi Trap affinity chromatography. The MTT and chicken embryo chorioallantoic membrane assay demonstrated that the human EDN produced from H. polymorpha inhibited in vitro the proliferation of human umbilical vein endothelial cells and in vivo the neovascularization induced by bFGF.     

Expression, purification, and characterization of recombinant fibulin-5 in a prokaryote expression system

Fibulin-5 is a widely expressed, integrin-binding extracellular matrix protein that mediates endothelial cell adhesion and scaffolds cells to elastic fibers. To investigate anti-angiogenesis activities and context-specific activities on responsive cells of recombinant fibulin-5 (rfibulin-5) expressed in Escherichia coli, the cDNA of fibulin-5 cloned from a human placenta cDNA library was inserted into the pET32a (+) vector to allow fibulin-5 expression as a Trx fusion protein. The fusion protein Trx-fibulin-5, expressed as insoluble inclusion bodies, was solubilized and its resulting expression level reached to 15% of the total cell protein. The Trxfibulin-5 was purified effectively by N²⁺-chelating chromatography and then identified by Western blotting analysis with an anti-His tag antibody. The purified Trx-fibulin-5 was refolded by dialysis against redox reagents, and the rfibulin-5 released from the fusion protein by enterokinase cleavage was purified using a RESOURCE RPC column. The final purified rfibulin-5 effectively inhibited angiogenesis in chicken embryos in a dose-dependent manner through a chorioallantoic membrane (CAM) assay. Additionally, rfibulin-5 potently suppressed in vitro proliferation of human umbilical vein endothelial cells, but stimulated that of human dermal fibroblasts. The expression and in vitro refolding of rfibulin-5 resulted in production of an active molecule with a yield of 2.1 mg/L.     

人纤溶酶原Kringle 1—4.5结构域的表达及活性鉴定

利用RT PCR的方法从人肝癌细胞株HepG2细胞内获得了编码人纤溶酶原 (hPlasminogen)的Kringle 1到 4及部分Kringle 5结构域 (简称K1- 4.5 )的cDNA ,将其克隆到表达载体pHIL S1中。将重组载体pHIL K 1- 4.5转化毕赤酵母GS115 ,得到的重组菌株用甲醇进行诱导表达 ,并利用赖氨酸亲和柱纯化重组蛋白质 ,得到的蛋白质纯度大于 95 %。重组蛋白质能特异性地按剂量依赖的方式抑制碱性成纤维细胞生长因子 (bFGF)刺激的牛主动脉内皮细胞 (BAEC)的增殖 ,浓度为 2mg/L达到最大抑制效果的 5 0 % ;K1- 4.5还能抑制bFGF引起的BAEC的迁移 ,作用浓度为 1mg/L时对BAEC迁移的抑制率为 40 %。     

Expression, purification, and bioactivity of human tumstatin from Escherichia coli

Tumstatin is a M(r) 28,000 C-terminal NC1 fragment of type alpha3 (IV) collagen that inhibits pathological angiogenesis and suppresses proliferation of endothelial cells and growth of tumors. We report here high cytoplasmic expression of recombinant human tumstatin in Escherichia coli and its purification, in vitro refolding, and inhibitory activity analysis. Human tumstatin was expressed in the bacterial cytoplasm as an insoluble N-terminal polyhistidine tagged protein, which accounted for more than 30% of total bacterial protein in BL21 (DE3) cells. After extraction and solubilization in guanidine-HCl, recombinant protein was purified to homogeneity using a simple one-step Ni(2+)-chelate affinity chromatography and then refolded by dialysis against acidic pH buffers with gradually decreasing concentrations of denaturant. The renatured recombinant tumstatin could specifically inhibit endothelial cell proliferation in a dose-dependent manner, and suppress bFGF-induced angiogenesis in chick embryo chorioallantoic membrane and tumor growth in mouse B16 melanoma xenograft models.     

人血管抑素 Kringles 1-3 的表达纯化及生物学活性研究

人血管抑素包含了4个环饼状结构域(Kringle),是一个有效的血管生成抑制因子。采用PCR方法从人胚肝cDNA文库中扩增了人血管抑素Kringles 1-3的基因,重组于pPIC9K载体中,获得重组载体pPIC9K-K1-3,然后转化毕赤酵母细胞GS115,获得重组菌株。K1-3蛋白在5 L发酵罐的表达量达41.2 mg/L,发酵液上清经过浓缩、透析,然后用Lysine Sepharose 4B层析柱纯化,得到的K1-3蛋白纯度大于98%,纯化回收率达到95%以上。K1-3能明显抑制bFGF刺激的人微血管内皮细胞的迁移,达到抑制效果为50%时所需的蛋白浓度(IC₅₀)为1.86 μg/ml。K1-3也能抑制鸡胚绒毛尿囊膜血管的生长,抑制率达95%。为应用人血管抑素Kringles 1-3治疗肿瘤奠定了初步实验基础。     

Antiangiogenic potential of 10-hydroxycamptothecin

To investigate the antiangiogenic potential of 10-hydroxycamptothecin (HCPT), the proliferation of human microvascular endothelial cells (HMEC) and seven human tumor cell lines were detected by SRB assay, and the endothelial cell migration and tube formation were assessed using two in vitro model systems. Also, inhibition of angiogenesis was determined with a modification of the chick embryo chorioallantoic membrane (CAM) assay in vivo. Morphological assessment of apoptosis was performed by fluorescence microscope. HCPT 0.313-5 micromol x L(-1) treatment resulted in a dose-dependent inhibition of proliferation, migration and tube formation in HMEC cells, and HCPT 6.25-25 nmol x egg(-1) inhibited angiogenesis in CAM assay. HCPT 1.25-5 micromol x L(-1) elicited typical morphological changes of apoptosis including condensed chromatin, nuclear fragmentation, and reduction in volume in HMEC cells. HCPT significantly inhibited angiogenesis both in vitro and in vivo at relatively low concentrations, and this effect was related with induction of apoptosis in HMEC cells. These results taken collectively suggest that HCPT may be a potent antiangiogenetic and cytotoxic drug and further investigation is warranted.     

人肿瘤抑素(Tumstatin)在E.coli中的克隆、表达及活性分析

从人胚肾2 93细胞中扩增肿瘤抑素(tumstatin)基因,进行原核表达,纯化和生物活性检测.利用原核表达载体pMAL c2在大肠杆菌BL2 1中表达肿瘤抑素,经AmyloseResin亲和层析柱和QSepharoseFastFlow柱纯化,通过体外内皮细胞增殖、内皮细胞凋亡和鸡尿囊绒膜新生血管生成试验检测其抑制活性.MBP tumstatin在BL2 1中表达率约2 0 % ,肿瘤抑素纯度可达95 % .肿瘤抑素可明显抑制内皮细胞增殖(IC50 约为15 μg ml)、诱导内皮细胞凋亡和抑制鸡尿囊绒膜新生血管生成.研究结果表明,肿瘤抑素对内皮细胞具有明显的抑制作用,提示其在肿瘤治疗中有潜在的应用前景.     

血管生成抑制因子K4K5 Cdna基因的克隆及其在毕赤酵母中的表达

应用PCR方法,扩增人纤溶酶原cDNA基因中K4K5 cDNA片段,与酵母表达载体pPIC9K重组,获得表达质凿p9kkk-18。该质粒转化毕赤酵母菌GS115,用G418－YPD筛选高拷贝表型,PCR筛选K4K5 cDNA与酵母染色体整全形成的阳性克隆,阳性克隆用甲醇诱导表达。表达产物r-K4K5分子量约21.5kD,占分泌总蛋白80％以上,产物浓度为150－250mg/L。初步纯化产物抑制牛毛细血管内皮（BCE）细胞增殖与鸡胚绒毛尿囊膜（CAM）新生血管生成。     

Expression of liver-targeting peptide modified recombinant human endostatin and preliminary study of its biological activities

Recombinant human endostatin (rEndostatin or endostar) has been shown to inhibit endothelial cells proliferation, migration, and angiogenesis and exhibits a broad spectrum of activities against solid tumors. However, rEndostatin is easily degradable and evenly distributed to all tissues. Selectively delivering rEndostatin to the lesion site might be more potent. The circumsporozoite protein (CSP) coats the malarial sporozoite and targets the liver for infection; I-plus of N end of CSP could specifically bind to the liver. Based on this, we hypothesize the fusion protein with introducing the CSP I-plus sequence into rEndostatin (rES-CSP) of which not only targets the liver, but also inhibits endothelial cells proliferation, migration, and tube formation. Therefore, it selectively reduces angiogenesis of hepatocellular carcinoma (HCC) and improves the anti-HCC effect. In this study, we synthesized a novel rES-CSP fusion gene by SOE-PCR and expressed the fusion protein in Escherichia coli BL2l (DE3). The suitable conditions were optimized by an orthogonal test (L(25)(5)(4)). The yields were 12 mg/l culture medium following refolding and purification on nickel-nitrilotriacetic acid (Ni-NTA) metal affinity chromatography matrices. The purified rES-CSP is specifically targeted to the hepatocyte and inhibited the proliferation and migration of human umbilical vein endothelial cells (HUVECs) in a dose-dependent manner and showed potent antiangiogenic capability on HUVECs tube formation assay and chick embryo chorioallantoic membrane (CAM) assay. These results lay the foundation for the further study of its targeting and anti-HCC in vivo and provide a feasible and convenient approach to produce liver-targeting drugs for treatment of the liver diseases.     

含人纤溶酶原K5基因的腺病毒载体制备和功能研究

应用PCR将人纤溶酶原信号肽序列引入K5cDNA基因 ,与真核表达载体pcDNA3重组 ,形成重组质粒pcDNA3K5 ,与穿梭质粒pShuttle重组得pShuttleK5 ,经与腺病毒DNA重组 ,PCR鉴定正确 ,即为pAd K5。脂质体法将其转染 2 93细胞后 ,制备细胞裂解液 ;噬斑分析法测定病毒滴度为 5× 10 8pfu mL。将病毒以不同的感染系数 (MOI)感染人脐静脉内皮细胞株ECV30 4和人乳腺癌细胞株MDA MB 2 31,MTT法检测两者的增殖情况 :ECV30 4细胞增殖受抑制 ,而MDA MB 2 31细胞增殖未受明显影响。将感染病毒的ECV30 4细胞接种于ECMatrixTM胶 ,显示内皮细胞分化和毛细血管管腔形成受抑制。表明所构建的含人纤溶酶原K5基因的重组复制缺陷型腺病毒具有抑制ECV30 4细胞增殖、分化和管腔形成的作用而对MDA MB 2 31细胞的生长则无影响。     

重组人角质细胞生长因子-2基因克隆、表达、纯化与活性分析

 从人胚肺二倍体细胞KMB17中抽提总RNA ,经RT PCR扩增获得编码人角质细胞生长因子 2 (keratinocytegrowthfactor 2 ,KGF 2 )的cDNA .克隆于硫氧环蛋白表达载体pThioHisA ,序列分析表明与文献报道一致 .经IPTG诱导 ,在大肠杆菌BL2 1中实现高效表达 ,表达量可达菌体总蛋白 10 %～15 % .菌体超声破碎 ,上清经CM SepharoseFF阳离子交换 ,Heparin Sepharose亲和层析 ,Superdex 75凝胶过滤层析纯化得到重组人KGF 2 ,纯度高于 95 % .生物活性分析表明 ,它能够促进成纤维细胞NIH 3T3的增殖 ,诱导鸡胚背根神经结神经轴突的生长 ,促进鸡胚尿囊膜血管生成 .研究结果表明 ,获得了 95 %纯度的具有生物学活性的重组人KGF 2 ,为进一步的基础与应用研究提供了基础     

人纤溶酶原饼环区5基因的原核表达及活性测定

 人纤溶酶原饼环区 5 (hPgnK5 )是新的血管生成抑制因子 .PCR法改造hPgnK5基因 ,所得hPgnK5基因包括编码人纤溶酶原C4 62 到P54 4共 83个氨基酸残基 ,而且在 5′ ,3′分别引入了EcoRⅠ和BamHⅠ位点 .以pThiohisA构建hPgnK5基因原核表达载体 ,在大肠杆菌TOP10中表达该蛋白 .通过柱层析法获得hPgnK5纯化蛋白 .免疫印迹反应表明该蛋白具有hPgnK5免疫活性 .体外实验表明 ,该蛋白具有抑制血管内皮细胞增殖活性 .提示hPgnK5可能具有良好应用前景     

基质金属蛋白酶-2 C端片段PEX的原核表达及其对血管发生的抑制作用

为了克隆表达鸡的基质金属蛋白酶-2(MMP-2)的C端片段PEX,并探讨其对血管发生的抑制作用,利用RT-PCR从鸡胚成纤维细胞克隆MMP-2 C端片段PEX,构建原核表达载体pCal-n-PEX;转化大肠杆菌BL21(DE3)-pLys,异丙基β-D硫代半乳糖苷（IPTG）诱导产生PEX融合蛋白,包涵体蛋白用盐酸胍法变性、复性;生长曲线观察PEX融合蛋白对人脐静脉血管内皮细胞增殖的影响;鸡胚绒毛尿囊膜血管发生实验研究其对血管发生的抑制作用.结果表明融合蛋白CBP/PEX具有抑制人脐静脉血管内皮细胞的生长和鸡胚绒毛尿囊膜血管发生的作用.提示PEX是有待进一步开发的潜在抑制血管发生的药物.